PL3790554T3 - Kompozycja farmaceutyczna do kontrolowanego uwalniania treprostynilu - Google Patents
Kompozycja farmaceutyczna do kontrolowanego uwalniania treprostyniluInfo
- Publication number
- PL3790554T3 PL3790554T3 PL19799941.0T PL19799941T PL3790554T3 PL 3790554 T3 PL3790554 T3 PL 3790554T3 PL 19799941 T PL19799941 T PL 19799941T PL 3790554 T3 PL3790554 T3 PL 3790554T3
- Authority
- PL
- Poland
- Prior art keywords
- treprostinil
- pharmaceutical composition
- controlled release
- release
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667889P | 2018-05-07 | 2018-05-07 | |
| US201862670875P | 2018-05-14 | 2018-05-14 | |
| PCT/US2019/030841 WO2019217271A1 (en) | 2018-05-07 | 2019-05-06 | Pharmaceutical composition for controlled release of treprostinil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3790554T3 true PL3790554T3 (pl) | 2026-03-30 |
Family
ID=68384347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19799941.0T PL3790554T3 (pl) | 2018-05-07 | 2019-05-06 | Kompozycja farmaceutyczna do kontrolowanego uwalniania treprostynilu |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11229616B2 (pl) |
| EP (2) | EP3790554B1 (pl) |
| JP (1) | JP7140418B2 (pl) |
| KR (2) | KR102750750B1 (pl) |
| CN (2) | CN118615249A (pl) |
| AU (1) | AU2019266171B2 (pl) |
| BR (1) | BR112020020127A2 (pl) |
| CA (1) | CA3099411A1 (pl) |
| DK (1) | DK3790554T3 (pl) |
| ES (1) | ES3058530T3 (pl) |
| FI (1) | FI3790554T3 (pl) |
| HR (1) | HRP20260019T1 (pl) |
| IL (1) | IL278513B (pl) |
| LT (1) | LT3790554T (pl) |
| MX (2) | MX2020011323A (pl) |
| PL (1) | PL3790554T3 (pl) |
| PT (1) | PT3790554T (pl) |
| RS (1) | RS67616B1 (pl) |
| SG (1) | SG11202011045VA (pl) |
| SI (1) | SI3790554T1 (pl) |
| SM (1) | SMT202600005T1 (pl) |
| TW (1) | TWI696471B (pl) |
| WO (1) | WO2019217271A1 (pl) |
| ZA (1) | ZA202006942B (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL278513B (en) | 2018-05-07 | 2022-09-01 | Pharmosa Biopharm Inc | A pharmaceutical preparation for the controlled release of treprostinil |
| TWI757739B (zh) * | 2019-05-14 | 2022-03-11 | 國邑藥品科技股份有限公司 | 包含弱酸藥物之醫藥組成物及其用途 |
| CN120076792A (zh) * | 2022-09-30 | 2025-05-30 | 上海济昀生物科技有限公司 | 一种脂质体药物组合物及其制备方法和应用 |
| TW202416936A (zh) * | 2022-09-30 | 2024-05-01 | 大陸商上海濟煜醫藥科技有限公司 | 脂質體及其製備方法和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082664A (en) * | 1987-05-22 | 1992-01-21 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
| IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| AU4981896A (en) | 1995-02-14 | 1996-09-04 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering liposome-loadable drugs |
| WO1996032930A1 (en) | 1995-04-18 | 1996-10-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
| AU2003298738A1 (en) * | 2002-11-26 | 2004-06-18 | Su-Ming Chiang | Liposomal formulations |
| ES2622471T5 (es) * | 2003-05-22 | 2020-07-23 | United Therapeutics Corp | Compuestos y procedimientos para la administración de análogos de prostaciclina |
| WO2006027787A1 (en) | 2004-09-09 | 2006-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal compositions of glucocorticoid and glucocorticoid derivatives |
| WO2007049279A2 (en) * | 2005-10-26 | 2007-05-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A liposomal combination and uses thereof |
| AU2006307460A1 (en) | 2005-10-26 | 2007-05-03 | New York University | A method for preparing liposomes and uses thereof |
| EP2026816B1 (en) * | 2006-05-15 | 2018-10-24 | United Therapeutics Corporation | Treprostinil administration using a metered dose inhaler |
| CN102164487A (zh) * | 2008-09-25 | 2011-08-24 | 阿拉迪姆公司 | 曲前列素的深肺部递送 |
| US9713591B2 (en) * | 2008-10-07 | 2017-07-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same |
| JP5960434B2 (ja) * | 2009-02-18 | 2016-08-02 | アラダイム コーポレーション | 肺送達のためのｐＨ調節された製剤 |
| CN101703471B (zh) * | 2009-11-18 | 2011-08-10 | 中国药科大学 | 一种改良的硫酸铵梯度法制备脂质体的方法 |
| EP2531175A2 (en) * | 2010-02-01 | 2012-12-12 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
| AU2013351934B2 (en) * | 2012-11-30 | 2018-03-29 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| US20180361342A1 (en) | 2015-12-08 | 2018-12-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for Preparing Liposome |
| TWI754659B (zh) * | 2016-08-08 | 2022-02-11 | 台灣微脂體股份有限公司 | 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組 |
| TWI728255B (zh) | 2017-07-24 | 2021-05-21 | 國邑藥品科技股份有限公司 | 包含弱酸藥物之脂質體組成物及其用途 |
| IL278513B (en) | 2018-05-07 | 2022-09-01 | Pharmosa Biopharm Inc | A pharmaceutical preparation for the controlled release of treprostinil |
-
2019
- 2019-05-06 IL IL278513A patent/IL278513B/en unknown
- 2019-05-06 PL PL19799941.0T patent/PL3790554T3/pl unknown
- 2019-05-06 AU AU2019266171A patent/AU2019266171B2/en active Active
- 2019-05-06 FI FIEP19799941.0T patent/FI3790554T3/fi active
- 2019-05-06 TW TW108115577A patent/TWI696471B/zh active
- 2019-05-06 SG SG11202011045VA patent/SG11202011045VA/en unknown
- 2019-05-06 LT LTEPPCT/US2019/030841T patent/LT3790554T/lt unknown
- 2019-05-06 US US16/404,272 patent/US11229616B2/en active Active
- 2019-05-06 CN CN202410622878.2A patent/CN118615249A/zh active Pending
- 2019-05-06 SM SM20260005T patent/SMT202600005T1/it unknown
- 2019-05-06 JP JP2020562721A patent/JP7140418B2/ja active Active
- 2019-05-06 PT PT197999410T patent/PT3790554T/pt unknown
- 2019-05-06 ES ES19799941T patent/ES3058530T3/es active Active
- 2019-05-06 KR KR1020237041479A patent/KR102750750B1/ko active Active
- 2019-05-06 KR KR1020207031676A patent/KR102610141B1/ko active Active
- 2019-05-06 MX MX2020011323A patent/MX2020011323A/es unknown
- 2019-05-06 DK DK19799941.0T patent/DK3790554T3/da active
- 2019-05-06 WO PCT/US2019/030841 patent/WO2019217271A1/en not_active Ceased
- 2019-05-06 HR HRP20260019TT patent/HRP20260019T1/hr unknown
- 2019-05-06 CN CN201980029011.3A patent/CN112384224B/zh active Active
- 2019-05-06 EP EP19799941.0A patent/EP3790554B1/en active Active
- 2019-05-06 RS RS20260017A patent/RS67616B1/sr unknown
- 2019-05-06 EP EP25207753.2A patent/EP4714451A2/en active Pending
- 2019-05-06 SI SI201931011T patent/SI3790554T1/sl unknown
- 2019-05-06 BR BR112020020127-8A patent/BR112020020127A2/pt unknown
- 2019-05-06 CA CA3099411A patent/CA3099411A1/en active Pending
-
2020
- 2020-10-26 MX MX2023011701A patent/MX2023011701A/es unknown
- 2020-11-06 ZA ZA2020/06942A patent/ZA202006942B/en unknown
-
2021
- 2021-10-27 US US17/511,819 patent/US11833125B2/en active Active
-
2023
- 2023-10-24 US US18/493,581 patent/US20240050387A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250196A0 (en) | Solid dosage form composition for buccal or sublingual administration of cannabinoids | |
| DK3648747T3 (da) | Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler | |
| DK3785733T3 (da) | Farmaceutisk sammensætning til behandling af autisme | |
| DK3634468T5 (da) | Fast sammensætning til oral indgivelse | |
| DK3116491T3 (da) | Farmaceutiske sammensætninger af terapeutisk aktive forbindelser | |
| DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
| DK3735228T3 (da) | Programmerbar farmaceutiske sammensætninger til krono-lægemiddelfrigivelse | |
| HUE049606T2 (hu) | Eljárás flavonoid inklúziós vegyületek elõállítására | |
| EP3742228A4 (en) | PHOTOPOLYMER COMPOSITION | |
| PL3661373T3 (pl) | Kompozycja farmaceutyczna na niedokrwistość | |
| EP3403655C0 (en) | COMPOSITION TO INCREASE THE EXPRESSION OF PGC-1 ALPHA | |
| PL3790554T3 (pl) | Kompozycja farmaceutyczna do kontrolowanego uwalniania treprostynilu | |
| FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
| EP3429589A4 (en) | PHARMACEUTICAL COMPOSITION OF NILOTINIB | |
| IL258852A (en) | Sustained release formulations of local anesthetics | |
| EP2968698A4 (en) | COMPOUNDS AND COMPOSITIONS FOR ACTIVE COMPOSITION | |
| ZA201902379B (en) | Extended release pharmaceutical composition of clozapine | |
| EP3560902A4 (en) | Composition for artificial marble | |
| EP3582759A4 (en) | BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF PRE-ORDIOXETINE HYDROBROMIDE | |
| DK2957280T3 (da) | Farmaceutisk faststofsammensætning af cytisin og fremgangsmåde til fremstilling deraf | |
| EP3302477A4 (en) | PHARMACEUTICAL FORMULATIONS FOR THE DELAYED RELEASE OF SEBACOYLDINALBUPHINESTER | |
| ES1229119Y (es) | Mecanismo de liberacion rapida para conexion desmontable de dos objetos | |
| HUE055374T2 (hu) | Eljárás Lenvatinib elõállítására | |
| EP3630074C0 (en) | TAPENTADOL SUSTAINED-RELEASE ORAL MULTI-PARTICLE DOSAGE FORM | |
| HUE047748T2 (hu) | Eljárás aminotiolészter vegyületek és sóik elõállítására |